What were the notable results of the TRuE-V1 and TRuE-V2 trials on ruxolitinib for vitiligo?Featuring David Rosmarin, MD | Vice Chair of Education and ResearchTufts Medical CenterBoston, MA | Published May 01, 2024Loading...Related MediaPowered by Polaris TM